Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CUD005 in patients with cirrhosis
NCT06296095Phase 1Enrolling by invitation
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Aug 2023
- Primary completion
- Oct 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CUD005 in Liver cirrhosis (LC), sponsored by The First Affiliated Hospital of USTC. Primary endpoints: Dose-Limiting Toxicity at 28 days and Maximum Tolerated Dose at 28 days. Started Aug 2023; status: enrolling by invitation.
02
Drugs
CUD005
03
Conditions
Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT06296095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06296095.